Atrial FibrillationPipeline Review, H2 2015
Summary
Global Markets Directs, Atrial FibrillationPipeline Review, H2 2015, provides an overview of the Atrial Fibrillations therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Atrial Fibrillation Overview 9
Therapeutics Development 10
Pipeline Products for Atrial Fibrillation - Overview 10
Pipeline Products for Atrial Fibrillation - Comparative Analysis 11
Atrial Fibrillation - Therapeutics under Development by Companies 12
Atrial Fibrillation - Therapeutics under Investigation by Universities/Institutes 14
Atrial Fibrillation - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Atrial Fibrillation - Products under Development by Companies 18
Atrial Fibrillation - Products under Investigation by Universities/Institutes 20
Atrial Fibrillation - Companies Involved in Therapeutics Development 21
ARCA biopharma, Inc. 21
Armetheon, Inc. 22
AstraZeneca Plc 23
Bristol-Myers Squibb Company 24
Cardiome Pharma Corp. 25
Daiichi Sankyo Company, Limited 26
Gilead Sciences, Inc. 27
Isis Pharmaceuticals, Inc. 28
Laboratoires Pierre Fabre SA 29
Nissan Chemical Industries, Ltd. 30
Nyken BV 31
Otsuka Holdings Co., Ltd. 32
Xention Limited 33
Atrial Fibrillation - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
AT-300 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BMS-394136 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BMS-919373 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
bucindolol hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
budiodarone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
edoxaban tosylate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
F-373280 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ISIS-CRPRx - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
NIP-151 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
NYK-1112 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
OMT-33 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
OPC-108459 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ranolazine ER - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecule to Block Kv1.5, Nav1.5, IKACh for Atrial Fibrillation - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
vanoxerine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
vernakalant hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
XEN-R0702 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
XEND-0103 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
XENR-0703 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
XENR-0706 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Atrial Fibrillation - Recent Pipeline Updates 74
Atrial Fibrillation - Dormant Projects 88
Atrial Fibrillation - Discontinued Products 92
Atrial Fibrillation - Product Development Milestones 94
Featured News & Press Releases 94
Sep 23, 2015: UK’s NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation 94
Sep 14, 2015: Laguna Pharmaceuticals Initiates Phase 3 Study of Vanoxerine in Atrial Fibrillation and Atrial Flutter 95
Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China 95
Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice" 96
Jun 25, 2015: Daiichi Sankyo’s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE 98
Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation 100
Apr 27, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe 101
Apr 15, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland 102
Apr 09, 2015: Cardiome Receives BRINAVESS Reimbursement Approval From Belgian Authorities 104
Feb 09, 2015: SAVAYSA (edoxaban) Now Available in U.S. Pharmacies 104
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107
List of Tables
Number of Products under Development for Atrial Fibrillation, H2 2015 10
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2015 20
Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H2 2015 21
Atrial Fibrillation - Pipeline by Armetheon, Inc., H2 2015 22
Atrial Fibrillation - Pipeline by AstraZeneca Plc, H2 2015 23
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2015 24
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp., H2 2015 25
Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 26
Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H2 2015 27
Atrial Fibrillation - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 28
Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H2 2015 29
Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H2 2015 30
Atrial Fibrillation - Pipeline by Nyken BV, H2 2015 31
Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 32
Atrial Fibrillation - Pipeline by Xention Limited, H2 2015 33
Assessment by Monotherapy Products, H2 2015 34
Number of Products by Stage and Target, H2 2015 36
Number of Products by Stage and Mechanism of Action, H2 2015 38
Number of Products by Stage and Route of Administration, H2 2015 40
Number of Products by Stage and Molecule Type, H2 2015 42
Atrial Fibrillation Therapeutics - Recent Pipeline Updates, H2 2015 74
Atrial Fibrillation - Dormant Projects, H2 2015 88
Atrial Fibrillation - Dormant Projects (Contd..1), H2 2015 89
Atrial Fibrillation - Dormant Projects (Contd..2), H2 2015 90
Atrial Fibrillation - Dormant Projects (Contd..3), H2 2015 91
Atrial Fibrillation - Discontinued Products, H2 2015 92
Atrial Fibrillation - Discontinued Products (Contd..1), H2 2015 93
List of Figures
Number of Products under Development for Atrial Fibrillation, H2 2015 10
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 34
Number of Products by Top 10 Targets, H2 2015 35
Number of Products by Stage and Top 10 Targets, H2 2015 35
Number of Products by Top 10 Mechanism of Actions, H2 2015 37
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 37
Number of Products by Top 10 Routes of Administration, H2 2015 39
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 39
Number of Products by Top 10 Molecule Types, H2 2015 41
Number of Products by Stage and Top 10 Molecule Types, H2 2015 41
